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of Alzheimer’s disease. In mild cognitive impair-
ment (MCI), postmortem investigations have 
revealed the effect of tau pathology on the basal 
nucleus [5,6]. In addition, this loss of cholinergic 
activity in the basal and rostral forebrain may 
also be a crucial component since it is associ-
ated with cognitive impairment and behavioral 
changes in many types of dementia [6]. An 
increase in plaque density occurs in Parkinson’s 
patients treated with anticholinergics [7], which 
may explain some of the cognitive decline seen 
in these patients. 
“Despite some awareness of the 
potential harm of anticholinergic 
medicines, studies report 20–50% of 
those over the age of 65 years take at 
least one anticholinergic medication.”
In structural MRI studies, volume reduction 
in the basal forebrain nucleus has been observed 
in MCI [8]. In MCI, it has been shown with PET 
that the enzyme acetylcholinesterase is down-
regulated, particularly in those who later develop 
dementia [9]. Studies show an upregulation of the 
choline acetyltransferase in MCI followed by the 
progressive reduction in choline acetyltransferase 
as the clinical stage of dementia is reached [10]. 
This upregulation could be a compensation to 
stabilize presynaptic acetylcholine concentra-
tions in the face of degeneration of cholinergic 
neurons. With the evidence that anticholinergic 
drugs are a risk factor for dementia, there are 
two potential pathways for this link to dementia:
•	 A compensated cholinergic deficit at the pre-
dementia stages of Alzheimer’s disease is 
critically affected by these drugs, with the 
consequence of accelerated functional decline 
of cholinergic transmission;
•	 These drugs exert an inhibitory effect on the 
control of the inflammatory processes.
It has been demonstrated that peripheral immune 
responses can be inhibited by cholinergic vagal 
Old age is not a disease – it is strength and sur-
vivorship, triumph over all kinds of vicissitudes 
and disappointments, trials and illnesses. 
Recent publications have, however, high-
lighted one age-related adversity that has 
until recently been relatively overlooked [1–3]. 
Medications that block muscarinic cholinergic 
receptors may be associated with functional and 
cognitive decline. Areas of deficit highlighted 
in elderly cohort studies include error proneness 
[1] and psychomotor speed and executive func-
tion [3]. These studies, among others, have high-
lighted the fact that older people are at particu-
lar risk. These issues have been discovered from 
large cohort studies. This raises the question as 
to why older people are at particular risk.
Aging processes & the physiological 
effects of anticholinergic blockade
Normal neurological function consists of a 
dynamic equilibrium between inhibitory and 
facilitatory pathways, maintaining the coordi-
nation that is essential for balance, swallowing 
and eye movement. An unbalanced decrease 
in any neurotransmitter concentration ini-
tially results in an upregulation of postsynaptic 
receptors. Once this physiological response has 
failed to compensate, symptoms of disease begin 
to appear. 
Central neurological effects
With age, memory becomes less efficient. This 
may be a result of changes within the CNS, 
including fluid shift, ischemia, plaques and 
tangles. Anticholinergic drugs (e.g., the potent 
muscarinic blocker scopolamine) acutely impair 
cognitive function in elderly individuals and 
young volunteers [4]. 
Alzheimer’s disease is characterized by a cho-
linergic deficit caused by the degeneration of the 
cholinergic nucleus Meynert in the basal fore-
brain. There is increasing evidence from post-
mortem investigations and neuroimaging sug-
gesting that the basal forebrain nucleus is already 
affected at stages prior to dementia in the course 
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neurons. In the brain, cholinergic nicotinic 
receptors on microglia cells inhibit inflamma-
tory reactions [11]. Anticholinergic drugs may 
inhibit this immune regulatory process and 
may thereby accelerate neurodegeneration. This 
has been proposed as the underlying cause for 
poor outcome after anticholinergic delirium in 
elderly individuals [12], with a loss of control 
of microglia contributed to by medicines with 
anticholinergic effects.
Peripheral neurological effects
Aging is associated with a slowing of nerve con-
duction associated with a reduction in the insula-
tion of axons by myelin. Balance systems become 
less efficient, sway is greater and there is an 
increased risk of falling. These changes are exac-
erbated by the presence of one or more comor-
bid diseases, which may be neurological (e.g., 
Alzheimer’s dementia, stroke, Parkinson’s dis-
ease, or neuropathy) or mechanical (e.g., muscle 
weakness or osteoarthritis). 
As people get older they are exposed to an 
increasing array of medications to treat their 
multiple medical problems. The problem is 
exacerbated by over-adherence to clinical guide-
lines by clinicians and, in many cases, the fail-
ure to undertake a medication review by a more 
senior member of the medical profession in pri-
mary or secondary care at any subsequent con-
tact points. Older people are frequently exposed 
to pharmacological agents with either a direct 
or indirect affect on central nervous pathways. 
Such medicines may be used to treat mood or 
behavioral disorders, which may be comorbid 
with established neurological disease, such as 
dementia or Parkinson’s disease. 
“There is a need for better in vitro 
models of the effect of muscarinic 
blockade to establish threshold 
effects and also potential pathways 
to damage.”
The blood–brain barrier is less efficient with 
age and therefore increasing amounts of medi-
cation will cross this barrier. This can result in 
CNS effects that may not be expected or are more 
intense than usual. Systemic illness, particularly 
septicemia, may result in increased permeability 
of the blood–brain barrier and increased expo-
sure to medications, their metabolites and any 
consequent side effects [13].
While recognizing the need for medication 
clinically, dose adjustments may be required 
in the elderly who develop acute illnesses. 
This is because of the greater permeability of 
the blood–brain barrier. As yet, translational 
research is needed to guide when this is neces-
sary and which medications pose the greatest 
risk [13].
Pharmacology of anticholinergic 
medication effects
Many medications are deployed because of their 
well-known anticholinergic properties. These 
include antimuscarinics such as pro cyclidine 
for movement disorders, treatments for inconti-
nence including terolidine, medication to reduce 
intestinal motility such as hyoscine and inhalers 
for the treatment of chronic obstructive pulmo-
nary disease. Many other medications also have 
significant (and well-known) anticholinergic 
side effects, including tricyclic and selective 
serotonin reuptake inhibitor antidepressants, 
antipsychotics, antihypertensives and some anti-
Parkinsonian medications. Other widely used 
medications (e.g., the calcium channel blocker, 
nifedipine) have been identified as having a small 
anticholinergic effect. Despite some awareness 
of the potential harm of anticholinergic medi-
cines, studies report 20–50% of those over the 
age of 65 years take at least one anticholinergic 
medication [1,14]. With increasing availability 
and sensitivity of in vitro bioassays, the num-
ber of medications found to have a degree of 
anticholinergic effect is likely to increase. 
The most important clinical issue highlighted 
in recent studies is that a high proportion of 
the older population are exposed to multiple 
drugs with low anticholinergic activity, but 
that the cumulative burden of these medica-
tions over many years may be associated with 
accelerated cognitive decline and mortality [1,15]. 
Even more ‘modern’ medications, such as newer 
anti histamines have a significant anti cholinergic 
effect, particularly if prescribed with other 
anticholinergic agents [16].
How can the anticholinergic effect or burden 
of medication be properly assessed in the clinical 
setting? Simple clinician-rated scoring systems 
have been suggested and used since 2001 [8,17]. 
Epidemiological and pharmacological studies 
have demonstrated good concurrent serum anti-
cholinergic activity and measures of cognitive 
impairment [1].
The anticholinergic effect or burden scale has 
so far only received limited validation. Work is 
underway to externally validate against other 
cohorts and disease states within the UK and 
the USA. It also remains unclear whether the 
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use of such scales (which were developed in a 
research setting for administration by experi-
enced clinical researchers) can be transferred 
into the clinical arena? [18]
A clinically useful scale to measure anti-
cholinergic burden should be easy and quick to 
use and acceptable in routine clinical practice, 
particularly prior to prescribing or during a med-
ication review. Further work needs to be under-
taken to examine whether such a scale could be 
used at the ‘coal face’ and whether there would 
be any clinical effect, for example the stopping 
of medications.
How should clinical practice change? There 
are two key issues to think about before pre-
scribing. The first is acceptance of the principle 
that although the anticholinergic effect of many 
medications is small, their cumulative effect 
may cause significant cognitive deterioration, 
particularly in older people who already have 
some degree of cognitive deficit. The second is 
to consider, as part of every medication review 
in an older person, whether each currently pre-
scribed medication is necessary and whether it 
could and should be stopped. One potential 
extended role for community pharmacists could 
be undertaking such reviews, particularly since 
many over-the-counter medicines have anti-
cholinergic activity [19]. One caveat to this is that 
people with established Alzheimer’s disease may 
be stable on their current medication and not 
exhibit, paradoxically, any medication-related 
decline in cognition, as the damage to their cho-
linergic systems has already occurred [3,15]. These 
patients may be able to tolerate a relatively large 
anticholinergic load, although there remains a 
significant risk of inducing delirium.
Future research
There is a need for better in vitro models of the 
effect of muscarinic blockade to establish thresh-
old effects and also potential pathways to dam-
age. This may subsequently enable develop ment 
of biomarkers to monitor cholinergic blockade. 
New assay models in development may also 
allow more systematic assessment of anticholin-
ergic effects and thereby identify treatments 
whose anticholinergic effects currently remain 
unknown. 
Practice recommendations
We recommend that clinicians: take a full 
medication history on admission (including 
over-the-counter drugs and supplements with 
such effects); be guided by a simple scale meas-
ure of anticholinergic blockade when optimiz-
ing patient’s medication; and avoid prescribing 
multiple anticholinergics as part of a broader 
strategy to avoid unnecessary polypharmacy.
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